Product Images Donepezil Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 16 images provide visual information about the product associated with Donepezil Hydrochloride NDC 69150-415 by Biomes Pharmaceuticals Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Donepezil Hydrochloride Structural Formula - image 01
Figure 1. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment. - image 02
Figure 2. Cumulative Percentage of Patients Completing 24 Weeks of Double-blind Treatment with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients who Completed the Study were: Placebo 80%, 5 mg/day 85%, and 10 mg/day 68%. - image 03
Figure 3. Frequency Distribution of CIBIC-plus Scores at Week 24. - image 04
Figure 4. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing the 15-week Study. - image 05
Figure 5. Cumulative Percentage of Patients with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients Within Each Treatment Group Who Completed the Study Were: Placebo 93%, 5 mg/day 90%, and 10 mg/day 82%. - image 06
Figure 6. Frequency Distribution of CIBIC-plus Scores at Week 12. - image 07
Figure 7. Time Course of the Change from Baseline in SIB Score for Patients Completing 6 Months of Treatment. - image 08
This appears to be a partial table or chart with incomplete headers and data. It is not possible to generate a useful description with the given information.*
Figure 8. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in SIB Scores. - image 09
Not available.*
Figure 9: Time Course of the Change from Baseline in ADCS-ADL-Severe Score for Patients Completing 6 Months of Treatment. - image 10
Figure 10. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in ADCS-ADL-Severe Scores. - image 11
Figure 11. Time-course of the Change from Baseline in SIB Score for Patients Completing 24 Weeks of Treatment. - image 12
Figure 12. Cumulative Percentage of Patients Completing 24 Weeks of Double-blind Treatment with Specified Changes from Baseline SIB Scores. - image 13
Figure 13. Frequency Distribution of CIBIC-plus Scores at Week 24. - image 14
This appears to be medication information regarding two forms of Donepezil HCI, one at 23mg/day and another at 10mg/day. There is also a table showing improved outcomes for patients, though it is difficult to determine what these outcomes are without additional information.*
image description - spl image label 10mg
NDC number 6915041603 corresponds to Donepezil, a medication prescribed in tablet form. Each tablet contains active ingredient Donepezil Hydrochloride USP, 10mg. The usual dosage details are enclosed in the package insert. The product is manufactured by BISMES Pharmaceuticals, LLC and comes in a 30 tablet pack. It is recommended to store the medication under controlled room temperature between 20-25°C.*
Donepezil Hydrochloride Tablets 23 mg Bottle Label - spl image label 5mg
This is a description of a medication called Donepezil. Each package contains 30 tablets, each containing 5mg of the active ingredient Donepezil Hydrochloride USP. The usual dosage information is contained in the enclosed package insert. The medication is only available through prescription and should be stored at room temperature (20° to 25° C). This particular medication is distributed by Biomes Pharmaceuticals, LLC.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.